{"id":"betaferon-bay86-5046","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Flu-like symptoms"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL534849","moleculeType":"Small molecule","molecularWeight":"301.78"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting interferon-gamma, Betaferon reduces the activation of immune cells and decreases the production of pro-inflammatory cytokines, leading to a decrease in inflammation and immune system activity. This mechanism of action is thought to be beneficial in the treatment of multiple sclerosis, a chronic autoimmune disease characterized by inflammation and demyelination in the central nervous system.","oneSentence":"Betaferon is an immunomodulatory drug that works by inhibiting the production of interferon-gamma, a cytokine involved in the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:59.354Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06053749","phase":"","title":"An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-03-20","conditions":"Multiple Sclerosis (MS)","enrollment":4},{"nctId":"NCT02486640","phase":"","title":"Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-08","conditions":"Multiple Sclerosis","enrollment":162},{"nctId":"NCT03808142","phase":"","title":"PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-02-20","conditions":"Multiple Sclerosis","enrollment":79},{"nctId":"NCT02749396","phase":"","title":"EPID Multiple Sclerosis Pregnancy Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-02","conditions":"Multiple Sclerosis","enrollment":2089},{"nctId":"NCT03134573","phase":"","title":"Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-15","conditions":"Multiple Sclerosis","enrollment":96},{"nctId":"NCT02652091","phase":"","title":"Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":146},{"nctId":"NCT03577977","phase":"","title":"Betaferon Use in Children and Adolescents With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-01","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT03408093","phase":"","title":"Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-02-03","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT01491100","phase":"","title":"Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-04-30","conditions":"Multiple Sclerosis","enrollment":1085},{"nctId":"NCT02121444","phase":"","title":"BAY86-5046 (Betaseron), Non Interventional Studies","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-23","conditions":"Multiple Sclerosis","enrollment":151},{"nctId":"NCT00963833","phase":"","title":"Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12-17","conditions":"Multiple Sclerosis","enrollment":68},{"nctId":"NCT01706055","phase":"","title":"Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":"Multiple Sclerosis","enrollment":629},{"nctId":"NCT01436838","phase":"","title":"China Betaferon Adherence, Coping and Nurse Support Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":"Multiple Sclerosis, Chronic Progressive","enrollment":110},{"nctId":"NCT00370071","phase":"PHASE3","title":"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-11","conditions":"Multiple Sclerosis","enrollment":39},{"nctId":"NCT00787657","phase":"","title":"Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":1723},{"nctId":"NCT00928967","phase":"","title":"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":67},{"nctId":"NCT00902135","phase":"","title":"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":702},{"nctId":"NCT01076595","phase":"","title":"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Multiple Sclerosis","enrollment":73},{"nctId":"NCT00780455","phase":"PHASE4","title":"Rehabilitation Study in MS Patients","status":"TERMINATED","sponsor":"Bayer","startDate":"2008-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":4},{"nctId":"NCT00459667","phase":"PHASE3","title":"BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1420},{"nctId":"NCT00313976","phase":"PHASE3","title":"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)","status":"WITHDRAWN","sponsor":"Bayer","startDate":"","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT01354665","phase":"","title":"Depression and Fatigue in MS Patients Treated With Betaferon.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Multiple Sclerosis","enrollment":567},{"nctId":"NCT01414816","phase":"","title":"Betaferon® Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Multiple Sclerosis, Clinically Isolated System","enrollment":355},{"nctId":"NCT00873340","phase":"","title":"Physical Disability in Patients Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":83},{"nctId":"NCT00235989","phase":"PHASE2","title":"Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT00185211","phase":"PHASE3","title":"BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-08","conditions":"Multiple Sclerosis","enrollment":468},{"nctId":"NCT00317941","phase":"PHASE4","title":"Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-03","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":220},{"nctId":"NCT01184833","phase":"","title":"Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-09","conditions":"Multiple Sclerosis","enrollment":852},{"nctId":"NCT00206635","phase":"","title":"Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-01","conditions":"Multiple Sclerosis","enrollment":432},{"nctId":"NCT01233245","phase":"","title":"BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-04","conditions":"Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS)","enrollment":1077},{"nctId":"NCT01235455","phase":"","title":"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":10},{"nctId":"NCT00882453","phase":"","title":"Physical Activity and Fatigue in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-08","conditions":"Multiple Sclerosis","enrollment":1739},{"nctId":"NCT01071694","phase":"","title":"QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2011-01","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":""},{"nctId":"NCT00544037","phase":"","title":"BENEFIT Extension Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-09","conditions":"Multiple Sclerosis","enrollment":283},{"nctId":"NCT01031459","phase":"","title":"Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Multiple Sclerosis","enrollment":176},{"nctId":"NCT00461396","phase":"","title":"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":104},{"nctId":"NCT00893217","phase":"PHASE2","title":"BEYOND Pilot Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":71},{"nctId":"NCT00099502","phase":"PHASE3","title":"BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":2244},{"nctId":"NCT00185250","phase":"PHASE2","title":"Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Cardiomyopathies, Heart Diseases","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Betaferon, BAY86-5046","genericName":"Betaferon, BAY86-5046","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Betaferon is an immunomodulatory drug that works by inhibiting the production of interferon-gamma, a cytokine involved in the immune response. Used for Relapsing-remitting multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}